Lisata Therapeutics, Inc. (LSTA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on June 17, 2025, by Lisata Therapeutics, Inc., a Delaware corporation. The filing updates investors on the Company's financial condition and includes a corporate presentation intended for investor and industry conferences.
Key Financial Metrics
The filing references data from the Company's 10-Q for the period ended March 31, 2025:
- Cash and Equivalents: Approximately $25.8 million in cash, cash equivalents, and marketable securities.
- Liquidity Runway: Previously estimated to support operations into Q3 2026; now revised to support operations into Q4 2026.
- Revenue, Profit, and Debt: The filing text does not provide specific values for revenue, net income, operating margins, or debt levels.
Material Changes
The primary material change disclosed is an extension of the liquidity runway. Management has revised its projection, stating that available funds will now support current operations into the fourth quarter of 2026, an improvement from the prior estimate of the third quarter of 2026.
Guidance, Outlook, and Risks
Outlook: The Company expects its current capital base to sustain operations through Q4 2026 based on existing and planned activities.
Disclosure Note: The information in Item 2.02 and the attached presentation (Exhibit 99.1) is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings, except as expressly stated.
Investor Verification Checklist
- Verify the specific details of the "planned activities" referenced in the updated runway calculation.
- Review the attached Exhibit 99.1 (Corporate Presentation) for additional operational or clinical milestones not detailed in the 8-K text.
- Confirm the exact composition of the $25.8 million in marketable securities to assess liquidity constraints.
- Check for any subsequent filings regarding capital raises or changes in burn rate that may alter the Q4 2026 projection.